EPISODE · Feb 9, 2021 · 9 MIN
Should we still use high-dose melphalan in the era of novel agents?
from Multiple Myeloma Hub
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Nikhil C. Munshi, Dana-Farber Cancer Institute, Boston, US. We asked, Should we still use high-dose melphalan in the era of novel agents? In this podcast, Munshi discusses the role of high-dose chemotherapy combined with stem cell transplantation in the era of novel agents. Upon analyzing data from a genomic-focused study, he concludes that high-dose melphalan can still achieve good and deep responses, while maintenance therapy should also be an important treatment component for multiple myeloma. Hosted on Acast. See acast.com/privacy for more information.
What this episode covers
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Nikhil C. Munshi, Dana-Farber Cancer Institute, Boston, US. We asked, Should we still use high-dose melphalan in the era of novel agents? In this podcast, Munshi discusses the role of high-dose chemotherapy combined with stem cell transplantation in the era of novel agents. Upon analyzing data from a genomic-focused study, he concludes that high-dose melphalan can still achieve good and deep responses, while maintenance therapy should also be an important treatment component for multiple myeloma. Hosted on Acast. See acast.com/privacy for more information.
NOW PLAYING
Should we still use high-dose melphalan in the era of novel agents?
No transcript for this episode yet
Similar Episodes
Apr 6, 2026 ·25m
Mar 30, 2026 ·27m